11/04/2025
đ¨ GLP-1s & Your BOTOX: What the New Study Says and why your treatment may not last as longđ
If youâre taking a GLP-1 receptor agonist (like Ozempic, Mounjaro, or Wegovy) and also get type A neurotoxin like Botox, you need to see this! A new computational study suggests that GLP-1 medications may reduce the durability of your botulinum toxin treatments.
Here are the key statistics from the computational model:
* Chronic Migraine Treatment: The mean duration of effect for BoNT-A (Botox) declined from 14.0 weeks (in controls) to as low as 11.8 weeks in patients with high GLP-1 exposure.
* Aesthetic Treatments (Masseter Prominence): The mean duration of effect decreased from 20.1 weeks (in controls) to a minimum of 16.2 weeks.
* Drug Hierarchy: The study suggested the effect varied by drug, with the greatest reduction in duration modeled for tirzepatide (Mounjaro/Zepbound), followed by liraglutide, then dulaglutide, and finally semaglutide (Ozempic/Wegovy).
* The Cause: The reduction in durability was attributed primarily to synaptic modulation (~55%)âthe drugâs effect on nerve signalingâand lean-mass decline (~30%).
The Bottom Line: If youâre on a GLP-1, you may need to schedule your Botox touch-ups sooner than before. While not specifically implied, this would include compounded medications as well.
â ď¸ Always consult your healthcare provider and injector to discuss any medications you are taking and to tailor your treatment plan!
The Study and Link:
* Title: Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications
* Link (PubMed): Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A